KLVFF | 183746-61-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: KLVFF
• 英文别名: L-Phenylalaninamide, L-lysyl-L-leucyl-L-valyl-L-phenylalanyl-；(2S)-2,6-diamino-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]hexanamide
• CAS: 183746-61-4
• 化学式: C₃₅H₅₃N₇O₅
• 分子量: 651.85
• InChiKey: QCXKXDGNJUNIQA-IIZANFQQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  47
• 可旋转键数：
  20
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  212
• 氢给体数：
  7
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  Rink amide resin 、 Fmoc-L-缬氨酸 、 Fmoc-L-亮氨酸 、 Fmoc-L-苯丙氨酸 、 N-alpha-芴甲氧羰基-N-epsilon-叔丁氧羰基-L-赖氨酸 在 1-羟基苯并三唑 、 N,N'-二异丙基碳二亚胺 、 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 KLVFF
  参考文献：
  名称：

  γ-AApeptide-based small-molecule ligands that inhibit Aβ aggregation

  摘要：

  我们报告了一类新型δ³-A肽一珠一化合物（OBOC）文库的设计、合成、表征和评估，从中发现了一种小的δ³-A肽，能有效防止和分解 Aδ²的聚集。

  DOI：

  10.1039/c3cc46685j

文献信息

• METHODS OF SYNTHESIZING y-AAPEPTIDES, y-AAPEPTIDE BUILDING BLOCKS, y-AAPEPTIDE LIBRARIES, AND y-AAPEPTIDE INHIBITORS OF Ab40 AGGREGATES
  申请人：CAI Jianfeng

  公开号：US20160209422A1

  公开（公告）日：2016-07-21

  Embodiments of the present disclosure provide for γ-AApeptides, γ-AApeptide building blocks, methods of making γ-AApeptides and libraries of γ-AApeptides, methods of screening the γ-AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for γ-AApeptides that are inhibitors of Aβ peptide aggregation, methods of inhibiting and disassembling Aβ peptide aggregation, methods of inhibiting the toxicity of Aβ aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease.
• METHODS OF SYNTHESIZING GAMMA-AAPEPTIDES, GAMMA-AAPEPTIDE BUILDING BLOCKS, GAMMA-AAPEPTIDE LIBRARIES, AND GAMMA-AAPEPTIDE INHIBITORS OF ALPHA-BETA40 AGGREGATES
  申请人：Cai Jianfeng

  公开号：US20170232055A1

  公开（公告）日：2017-08-17

  Embodiments of the present disclosure provide for γ-AApeptides, γ-AApeptide building blocks, methods of making γ-AApeptides and libraries of γ-AApeptides, methods of screening the γ-AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for γ-AApeptides that are inhibitors of Aβ peptide aggregation, methods of inhibiting and disassembling Aβ peptide aggregation, methods of inhibiting the toxicity of Aβ aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease.